share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Topper David Joseph

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities

Arcutis Biotherapeutics | 4：持股變動聲明
SEC announcement ·  04/11 20:36
Moomoo AI 已提取核心訊息
David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has been granted 110,000 shares of common stock on April 10, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of compensation or a similar incentive plan. Following this transaction, Topper directly owns a total of 110,000 shares in the company. The grant of shares to a high-level executive is a common practice in the industry and reflects the company's commitment to aligning the interests of its executives with those of its shareholders.
David Joseph Topper, the Chief Financial Officer of Arcutis Biotherapeutics, has been granted 110,000 shares of common stock on April 10, 2024. The transaction, which was completed on the same day, was a grant with a transaction price of $0.00 per share, indicating that the shares were likely awarded as part of compensation or a similar incentive plan. Following this transaction, Topper directly owns a total of 110,000 shares in the company. The grant of shares to a high-level executive is a common practice in the industry and reflects the company's commitment to aligning the interests of its executives with those of its shareholders.
Arcutis Biotherapeutics首席財務官大衛·約瑟夫·託珀已於2024年4月10日獲得11萬股普通股。該交易於當天完成，是一筆贈款，交易價格爲每股0.00美元，這表明這些股票可能是作爲薪酬或類似激勵計劃的一部分授予的。在這筆交易之後，Topper直接擁有該公司共計110,000股股份。向高級管理人員授予股份是業內普遍的做法，反映了公司致力於協調高管利益與股東利益的承諾。
Arcutis Biotherapeutics首席財務官大衛·約瑟夫·託珀已於2024年4月10日獲得11萬股普通股。該交易於當天完成，是一筆贈款，交易價格爲每股0.00美元，這表明這些股票可能是作爲薪酬或類似激勵計劃的一部分授予的。在這筆交易之後，Topper直接擁有該公司共計110,000股股份。向高級管理人員授予股份是業內普遍的做法，反映了公司致力於協調高管利益與股東利益的承諾。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息